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The pharmacological administration of glucagon-like peptide-1 receptor (GLP-1R) 
agonists reduces blood pressure in type 2 diabetes and non-diabetic patients. This study tested 
the hypothesis that endogenous GLP-1R signaling influences the regulation of blood pressure. 
To this end, spontaneously hypertensive rats (SHR) and Wistar rats were treated with the GLP-
1R antagonist exendin-9 (Ex9) or vehicle for four weeks. Rats receiving the GLP-1R agonist 
exenatide (Ex4) were used as an additional control. We found that blockade of baseline GLP-1R 
signaling by Ex9 increased systolic blood pressure (SBP) in both SHR and Wistar rats, compared 
to vehicle-treated animals, while Ex4 only reduced SBP in SHR. Higher SBP induced by Ex9 
was accompanied by reduced lithium clearance and lower levels of Na+/H+ exchanger isoform 3 
(NHE3) phosphorylation at the serine 552, indicative of increased proximal tubule sodium 
reabsorption. Additionally, urinary angiotensinogen (AGT) and renal cortical concentration of 
angiotensin II (Ang II) were enhanced by Ex9. Conversely, Ex4 decreased both urinary AGT and 
cortical Ang II, but exclusively in SHRs. Moreover, both SHR and Wistar rats treated with Ex9 
displayed hyperinsulinemia as compared to vehicle-treated rats, whereas Ex4 reduced fasting 
insulin concentration in SHR. Collectively, these results suggest that endogenous GLP-1R 
signaling exerts a physiologically relevant effect on blood pressure control, which may be 
attributable in part to its tonic actions on the proximal tubule NHE3-mediated sodium 
reabsorption, intrarenal renin-angiotensin system and/or insulin sensitivity. The possible role of 
impaired GLP-1R signaling in the pathogenesis of hypertension warrants further investigation.  
 




Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced through differential 
post-translational processing of the proglucagon protein by the enteroendocrine L cells1. Under 
physiological conditions, GLP-1 increases insulin secretion and suppresses glucagon release in a 
glucose-dependent manner2.  GLP-1 also increases insulin synthesis3 and insulin sensitivity in 
peripheral tissues4. All of these metabolic effects underscore the use of GLP-1 as a 
pharmacological target for treating type 2 diabetes (T2D). However, since native GLP-1 is 
rapidly degraded by the serine peptidase dipeptidyl peptidase-4 (DPP4)5, DPP4 inhibitors, and 
GLP-1 receptor (GLP-1R) agonists that are resistant to DPP4 degradation emerged as preferred 
anti-T2D drugs.  
The glycemic effects of GLP-1 are primarily mediated through binding to its selective 
G protein-coupled receptor GLP-1R and formation of cAMP via Gs signaling6. Activation of the 
GLP-1R also leads to extra-glycemic effects in numerous tissues, including the kidneys. GLP-1R 
agonists have been demonstrated to induce diuresis and natriuresis, at least in part through 
inhibition of Na+/H+ exchanger isoform 3 (NHE3) in the renal proximal tubule7. GLP-1R 
induced cAMP activation also confers renal benefits on the diseased kidney, including 
antialbuminuric, antioxidant, and anti-inflammatory effects8.   
Recent clinical studies indicate that the administration of GLP-1R agonists reduces blood 
pressure levels in diabetic patients when compared to placebo9-11. The antihypertensive effect of 
GLP-1R agonists has also been observed in a variety of non-diabetic models of hypertension, 
including Dahl salt-sensitive rats12, in angiotensin II-induced hypertension13, 14 and 
spontaneously hypertensive rats (SHR)15. Collectively, the results from these pre-clinical studies 
suggest that the antihypertensive effects of GLP-1 are mediated by its action on the kidneys to 
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induce natriuresis, on the endothelial cells to promote vasodilation and on the brainstem 
catecholamine neurons to attenuate sympathetic nerve activity. GLP-1R agonists have been 
demonstrated to counteract the actions of angiotensin II on the kidney16, which may represent 
other potential antihypertensive and renoprotective mechanism of these therapeutic agents. 
Notably, a study conducted in healthy subjects demonstrates a negative correlation between 
postprandial GLP-1 levels and systolic blood pressure (SBP)17, suggesting that endogenous GLP-
1 may have blood pressure-lowering properties. Interestingly, we have previously found that 
acute blockade of the GLP-1R with its peptide exendin-9 exerts anti-natriuretic and antidiuretic 
effects in Wistar rats18. These results provide novel evidence that GLP-1 is a physiologically 
relevant natriuretic factor that contributes to sodium balance. However, it remains to be 
established whether endogenous GLP-1 may play a role in blood pressure control, and if so, the 
mechanisms involved. Therefore, this study aimed to test the hypothesis that long-term GLP-1R 
blockade increases blood pressure in both normotensive and hypertensive rats. Besides, a 
combined strategy using the GLP-1R antagonist exendin-9 and the agonist exenatide was 
employed to gain insight into the molecular mechanisms underlying the blood pressure effects of 







The data that support the findings of this study are available from the corresponding 
author upon request. 
An expanded Material and Methods section is available in the online-only Data 
Supplement.  
Animals - All experiments were carried out following the ethical principles in animal 
research of the Brazilian College of Animal Experimentation and were approved by the 
Institutional Animal Care and Use Committee. Forty-day-old male spontaneously hypertensive 
rats (SHR, n = 54) and Wistar rats (n = 48) were randomized into three groups and treated twice-
daily with intraperitoneal injections of the GLP-1R antagonist exendin-9 (75 μg/kg/day), the 
GLP-1R agonist exenatide (10 μg/kg/day) or vehicle (0.9% saline) over 28 days. SBP was 
measured by tail-plethysmography at the start of the study (day 0) and thereafter weekly, 
commencing after treatment with exendin-9, exenatide, or saline. Five days before the end of 
treatment, rats were individually placed into metabolic cages for 24h urine collection. The 
diuretic and natriuretic responses to an acute extracellular volume expansion were evaluated 
three days before the end of the study. Oral Glucose Tolerance Test (OGTT) was performed two 
days before the end of treatment. On the last day of treatment, BP was measured by cannulation 
of the carotid artery in anesthetized rats. Arterial blood was collected at the time of death. Rats 
were killed by decapitation, and the kidneys were immediately removed for isolation of renal 
cortical membrane proteins and immunoblotting or tissue fixation for immunohistochemistry 
(Figure S1 and Table S1). 
Statistical analysis - Results are reported as means ± SEM with n indicating the number 
of rats unless otherwise stated. Comparisons among the groups were performed using one-way or 
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Long-term blockade of GLP-1R increases blood pressure in both hypertensive and 
normotensive rats  
Tail cuff BP was similar among the three groups of 40-day-old SHRs before treatment 
(Figure 1A). In vehicle-treated rats, tail-cuff BP increased significantly over the 4-week 
experimental time course, consistent with developing hypertension in SHRs. In rats receiving 
exendin-9, the hypertension was amplified compared to vehicle (Figure 1A), and at the end of 
the experiment, tail-cuff BP was 10 ± 2 mmHg higher than control. In contrast, the GLP-1R 
agonist exenatide attenuated the progressive rise in tail-cuff BP (Figure 1A), so that after 4 
weeks was 12 ± 1 mmHg lower than in untreated animals. Surprisingly, exendin-9 treatment also 
increased tail-cuff BP by 16 ± 2 mmHg in conscious Wistar rats, but in this case BP was not 
reduced by activation of GLP-1R by exenatide (Figure 1B).  
Next, we examined the effects of long-term blockade of GLP-1R on SBP and DBP in 
anesthetized SHRs and Wistar rats. In SHRs, we again found contrasting effects of exendin-9, 
which increased SBP compared to controls, and exenatide, which lowered SBP (Figure 1C). 
Normotensive Wistar rats treated with the GLP-1R antagonist exendin-9 also exhibited increased 
SBP compared to vehicle controls, whereas receptor agonism was without effect (Figure 1D). No 
significant differences were found in DBP among the three groups of SHRs (Figure 1E). DBP 
was also similar across all three groups of Wistar rats (Figure 1F). Heart rate was not different 
across treatment groups in either SHR or Wistar (data not shown).  
 
Long-term GLP-1R blockade impairs the acute renal natriuretic response  extracellular fluid 





Urine flow rate,  glomerular filtration rate (GFR) and the fractional excretion of sodium, 
examined by 24h urine collection at the end of the study, were similar and unchanging in all 
groups (Tables S2 and S3). This is consistent with steady state sodium-fluid balance since food 
and water intake were not different between groups. However, long-term blockade or activation 
of the GLP-1R altered the acute (3h) excretory response to an intraperitoneal bolus of isotonic 
saline (10% volume/body weight). Chronic exendin-9 treatement reduced the percentage of the 
fluid and sodium load that was excreted in both SHR and Wistar rats (Figure 2A-D). Conversely, 
the acute diuretic/natriuretic response of exenatide-treated SHR was higher than that of controls 
and exendin-9-treated SHRs (Figure 2A and 2C). Similar fluid and salt load percentages were 
excreted by control and exenatide-treated Wistar rats (Figure 2B and 2D).  
To evaluate whether changes at the rate of which the saline load was excreted by SHR 
and Wistar rats were accompanied by changes in proximal tubule sodium reabsorption, we 
measured the lithium clearance, an index of proximal tubular fluid delivery. As depicted in 
Figure 2, lithium clearance was decreased by exendin-9 and increased by exenatide when 
compared to SHR (Figure 2E) or Wistar rats (Figure 2F) that received vehicle.  
 
Long-term blockade of GLP-1R reduces PKA-mediated NHE3 phosphorylation in the renal 
cortex of SHRs and Wistar rats   
NHE3 is the primary pathway for sodium reabsorption in the proximal tubule apical 
membrane19. Therefore, we hypothesized that blockade of the GLP-1R signaling might be 
accompanied by stimulation of NHE3. To this end, we evaluated whether exendin-9 could alter 
NHE3 phosphorylation at the PKA consensus site serine 552 (PS552-NHE3) as a surrogate of 
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NHE3 activity since the levels of NHE3 phosphorylation at this residue negatively correlates 
with proximal tubule NHE3 transport function20, 21.  As illustrated in Figure 3A, long-term 
treatment with exendin-9 reduced the levels of PS552-NHE3 in the renal cortex of SHRs, 
whereas exenatide modestly increased it. A similar reduction in the levels of PS552-NHE3 was 
observed in the renal cortex of Wistar rats treated with exendin-9. In line with earlier studies 
evaluating the acute effect of exenatide on NHE37, long-term activation of the GLP-1R increased 
PS552-NHE3 levels in Wistar rats (Figure 3B). Conversely, total NHE3 protein abundance did 
not vary in response to either exendin-9 or exenatide treatments (Figure S2).  
 
Long-term blockade of GLP-1R increases renal cortical angiotensin II (Ang II) concentration 
in SHR and Wistar rats  
An activated intrarenal renin-angiotensin system (RAS) plays a crucial role in the 
pathogenesis of hypertension. We therefore evaluated the potential relationship between 
blockade of GLP-1R signaling and activation of the intrarenal renin-angiotensin system.  We 
first assessed whether long-term blockade of GLP-1R could alter the urinary excretion of 
angiotensinogen (AGT), which is known to provide a specific index of intrarenal RAS status22. 
As illustrated in Figure 4, exendin-9 treatment enhanced urinary excretion of AGT in both SHRs 
(Figure 4A) and Wistar rats (Figure 4B) as compared to their respective controls (vehicle-treated 
rats). Exenatide treatment reduced urinary AGT excretion, but only in SHRs (Figure 4A-B).  The 
systemic levels of AGT, evaluated by immunoblotting, remained unchanged in response to either 
exendin-9 or exenatide in both strains of rats (Figure S3).  
Next, to confirm the effect of GLP-1R blockade on intrarenal RAS, the levels of renal 
cortical Ang II concentration was measured. Indeed, renal cortical Ang II content was increased 
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by exendin-9 in both SHRs (Figure 4C) and Wistar rats (Figure 4D). Once again, exenatide 
treatment significantly reduced renal Ang II content in SHRs (Figure 4C) but did not alter it in 
Wistar rats when compared to saline-treated animals.  
 
Long term-blockade of GLP-1R leads to fasting hyperinsulinemia in normotensive rats, 
potentiates it in hypertensive rats and impairs insulin sensitivity in both rat strains   
Hyperinsulinemia results from an imbalance between insulin secretion and insulin 
sensitivity23. The association of hypertension, insulin resistance, and resultant hyperinsulinemia 
is well established24. Given the strong evidence suggesting that GLP-1R activation increases 
insulin sensitivity in peripheral tissues25, 26 and thereby reduces fasting hyperinsulinemia26, we 
tested the hypothesis that the effects of chronic blockade of GLP-1R on blood pressure could be 
associated with the worsening of insulin resistance.  
The fasting blood glucose levels were similar among the SHR groups (Table S2). 
However, the OGTT demonstrated a significant increase in the area under the curve (AUC) of 
the SHRs treated with exendin-9 as compared to vehicle-treated SHRs (Figure 5A), suggesting 
that GLP-1R blockade induces some degree of glucose intolerance in SHRs despite normal 
fasting glucose levels.  Conversely, exenatide reduced AUC in SHRs in comparison with 
controls (Figure 5A). In Wistar rats, fasting blood glucose levels and glucose tolerance were 
unaltered by treatment with exendin-9 (Table S3, Figure 5B); however, a reduction of AUC was 
observed in response to exenatide (Figure 5B). 
As also illustrated in Figure 5, serum insulin levels were increased in exendin-9 treated 
SHRs (Figure 5C) and Wistar rats (Figure 5D) compared to saline-treated controls. Notably, 
exenatide treatment reduced serum insulin levels of SHR rats to levels similar to those of saline-
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treated Wistar. Insulin resistance was confirmed by calculating the Homeostasis Model 
Assessment for Insulin Resistance (HOMA-IR) index (Figure 5E-F). Long-term blockade of 
GLP-1R increased the HOMA-IR index in both SHRs and Wistar rats as compared to their 
respective saline-treated group. Activation of GLP-1R by exenatide improved insulin resistance 
in SHRs but did not affect it in Wistar rats (Figure 5E-F). 
 
Long-term blockade of GLP-1R exacerbates renal damage in hypertensive rats 
Recent clinical and experimental studies have highlighted the potential renoprotective 
actions of GLP-1R agonists in diabetic nephropathy that seem to be mediated by pleiotropic 
effects independent from glycemic control27. Thus, we predicted that chronic blockade of the 
GLP-1R could potentiate the progression of renal damage, especially in SHRs. We found that 
four-week treatment with exendin-9 significantly raised the albumin to creatinine ratio (ACR) in 
SHRs and Wistar rats compared to the respective saline-treated control rats (Table S2-S3). 
Exenatide treatment decreased the ACR in hypertensive rats, but did not affect albuminuria in 
Wistar rats (Table S3).  Figure S4 shows that the myofibroblast activation marker α-SMA was 
higher in SHR treated with exendin-9 than in those which received vehicle (Figure S4A) and that 
the number of infiltrating macrophages in the renal cortex was increased also compared to 
vehicle-treated rats (Figure S4B). Conversely, the renal cortex of SHRs treated with exenatide 
displayed lower expression of α-SMA (Figure S4A) and a reduced number of infiltrated 
macrophages (Figure S4B) when compared with saline-treated SHR rats. Neither expression of 
α-SMA nor infiltration of macrophages were detected in the renal cortex of Wistar rats treated or 




Systemic administration of GLP-1R antagonist and agonist alters GLP-1R signaling in the 
renal cortex  
To determine whether the systemic infusion of exendin-9 or exenatide for four weeks 
affects GLP-1R signaling in the renal cortex of SHRs and Wistar rats, phosphorylation of PKA 
substrates were assessed by immunoblotting. As shown in Figure 6A, the levels of several 
phosphorylated PKA substrates were lower in the renal cortex of exendin-9-treated SHRs 
compared with SHRs that received saline. Conversely, the levels of phospho-PKA proteins were 
higher in the renal cortex of exenatide-treated vs. saline-treated SHR rats. As seen in Figure 6B, 
qualitatively similar effects of exendin-9 treatment were observed in Wistar, but the reduced 
phospho-PKA proteins were not statistically significant (78 ± 8 vs. 100 ± 1% Wistar-Ctrl, P = 
0.09). However, exenatide administration was capable of increasing the phosphorylation levels 






Previous studies from our laboratory and others have demonstrated that acute 
pharmacological stimulation of the GLP-1R induces diuresis and natriuresis by increasing GFR 
and inhibiting the main renal proximal tubule sodium reabsorption pathway, NHE3, in 
normotensive rats7, 28, 29. In addition, we have shown that acute blockade of the GLP-1R receptor 
provokes the opposite effect, i.e., decreases GFR and increases NHE3-mediated sodium 
reabsorption in the proximal tubule18, supporting the notion that endogenous GLP-1R signaling 
exerts a tonic natriuretic action that modulates sodium balance and may prevent volume 
expansion.  Herein, we provide novel evidence that long-term blockade of the endogenous GLP-
1R signaling by its antagonist exendin-9 intensifies blood pressure rise and exacerbates renal 
damage in hypertensive rats. Intriguingly, GLP-1R blockade also enhances blood pressure in 
normotensive rats, suggesting that endogenous GLP-1R signaling may contribute to 
physiological blood pressure homeostasis. Moreover, the results presented in this study suggest 
that the antihypertensive effects of baseline GLP-1R activation involve, at least in part, 
modulation on the proximal tubule NHE3-mediated sodium reabsorption, intrarenal renin-
angiotensin system and/or insulin sensitivity.  
Multiple clinical trials assessing the cardiovascular safety of the GLP-1R agonists have 
consistently shown that sustained treatment with these agents induces modest to significant 
reductions in systolic blood pressure of T2D hypertensive patients30-32. DBP is less consistently 
affected. Notably, a Japanese study that included 128 subjects from the general population 
indicated that the postprandial increase of GLP-1 in response to a glucose load inversely 
correlates with SBP17. Conversely, no significant association was detected between postprandial 
GLP-1 levels and DBP17. These reports are in line with our findings that show that long-term 
blockade of GLP-1R signaling enhances SBP but does not affect DBP in normotensive and 
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hypertensive rats. The fact that SBP is the predominant component affected by GLP-1R 
signaling in human subjects as well as in our current experimental study suggests that GLP-1R-
mediated blood pressure control is mainly due to its effects on extracellular volume homeostasis. 
This hypothesis is supported by the saline challenge experiments revealing that the blockade of 
GLP-1R by exendin-9 reduces the natriuretic/diuretic response to an acute extracellular volume 
expansion in both hypertensive and normotensive rats. Our data also indicate that rats treated 
with the GLP-1R antagonist exendin-9 ultimately maintain salt balance but a logical conclusion 
is that this comes at the expense of increased blood pressure.   
The natriuretic/diuretic response is dependent on extracellular fluid volume and body 
sodium content (perhaps reference the paper mentioned by the reviewer here: PMID: 4021315). 
We observed a blunted excxretory response to a saline load in exendin-9-treated rats, which 
points to underlying changes in extracellular fluid volume and may additionally reflect a 
decrease in GFR and/or an increase in tubular sodium reabsorption. In normotensive rats, the 
acute anti-natriuretic effect of exendin-9 is accompanied by a reduction in GFR and renal blood 
flow18. In contrast, these renal hemodynamic parameters are increased by acute GLP-1R 
activation, most likely due to the vasodilation of the afferent arterioles33. However, chronic 
modulation of GLP-1R signaling does not significantly change GFR in normotensive rats and 
thus hemodynamic actions are unlikely to contribute significantly to the reduced natriuretic 
response to volume expansion in these animals.  Notably, hypertensive rats are refractory to the 
acute GLP-1R-activation mediated renal vascular relaxation34.35 In line with these findings, we 
show herein that long-term blockade or activation of the GLP-1R receptor does not affect GFR 
in hypertensive rats.  
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Proximal tubule NHE3-mediated sodium reabsorption plays a crucial role in the pressure 
natriuresis response that maintains volume homeostasis and blunts further increases in blood 
pressure36. Our finding that higher blood pressure and impaired renal salt handling in 
hypertensive and normotensive rats treated with exendin-9 was associated with lower levels of 
NHE3-PS552 and higher lithium clearance suggests that long-term blockade of GLP-1R 
signaling elevates blood pressure at least in part by blunting the compensatory natriuretic 
response of the renal proximal tubule. In the kidneys, the GLP-1R is found only in the proximal 
tubule and glomerulus7. However, we cannot exclude the possibility that changes in renal GLP-
1R signaling may also exert indirect effects on other sodium transporters along the nephron of 
hypertensive and normotensive rats, either due to the changes in the sodium load that is delivered 
to the distal nephron, or to the actions that GLP-1 has been shown to exert in opposition to those 
of Ang II16.  
The RAS plays a determinant role in regulating blood pressure as well as sodium and 
water balance. Our study demonstrates that long-term blockade of GLP-1R activates intrarenal 
RAS. Thus, endogenous activation of the GLP-1R may prevent blood pressure elevation and 
volume expansion by downregulating intrarenal RAS. Indeed, several studies support the idea 
that GLP-1 is capable of counteracting the actions of systemic and renal Ang II13, 14, 16, 37. Skov 
and colleagues have found that systemic infusion of GLP-1 in young healthy males for 2-hours 
decreases the circulatory Ang II concentration37. The GLP-1R agonists exendin-414 and 
liraglutide13  mitigate increases of blood pressure rise in response to Ang II, at least in part due to 
its natriuretic actions. A cross-talk between GLP-1R and Ang II has also been shown in isolated 
mesangial cells from human kidneys, in which GLP-1 blocked the Ang II-induced increase in 
reactive oxygen species and activation of inflammatory mediators through a GLP-1R/PKA 
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signaling pathway16. Opposing effects of GLP-1 and Ang II are also observed with regard to 
proximal tubule NHE3 regulation38. While GLP-1 inhibits NHE3 by stimulating the cAMP/PKA 
signaling pathway and increasing the levels of NHE3-PS5527, 29, Ang II reduces cAMP/PKA-
mediated NHE3 phosphorylation at serine 552, leading to increased NHE3-mediated transport in 
renal proximal tubule cells38. Accordingly, long-term administration of exendin-9 lowers cortical 
NHE3-PS552 levels. This effect might be resultant from the coordinated actions of the direct 
blockade of the renal GLP-1R signaling by this antagonist coupled with the indirect activation of 
the angiotensin II receptor type 1 (AT1R)/inhibitory Gi protein due to exendin-9-induced 
augmentation of cortical Ang II content. Under physiological conditions, the natriuretic effects of 
endogenous activation of GLP-1R signaling might neutralize the cellular pathway triggered by 
Ang II in the renal proximal tubule, thereby contributing to the maintenance of sodium balance 
and blood pressure regulation. 
Insulin resistance and hyperinsulinemia aggravate hypertension, among other 
cardiovascular diseases24, 39.  In this context, our study shows that both hypertensive and 
normotensive rats treated with exendin-9 exhibit increased fasting serum insulin concentration 
and HOMA-IR index as compared to vehicle-treated rats. Indeed, our data indicate that long-
term blockade of the GLP-1R is able to worsen insulin sensitivity in SHRs and develop insulin 
resistance in Wistar rats. Hyperinsulinemia may occur as a compensatory mechanism of the 
pancreas to secrete higher amounts of insulin in the face of defects in the complex cascades of 
insulin receptor signaling, including insulin substrate 1/2 (IRS-1/2)/phosphoinositide 3-kinase 
(PI3K)/protein kinase B (AKT). In the kidney, insulin resistance is selective40 since IRS1 
signaling is impaired41, whereas IRS2 remains intact42, 43. The main effects arising from 
hyperstimulation of IRS2 in the kidneys are hyperfiltration and renal tubule-mediated sodium 
17 
 
retention41, 44.  Cumulative evidence indicates that hyperinsulinemia induces volume expansion 
and contributes to the development of hypertension, mainly by stimulating sodium reabsorption 
in the proximal tubule through NHE3 on the apical surface of the cell45 and by the 
sodium/bicarbonate cotransporter (NBCe1) on the basolateral surface41. Thus, it is tempting to 
speculate that hyperinsulinemia contributes to blood pressure increase in our experimental 
models via proximal tubule NHE3. Nevertheless, despite the observations that higher blood 
pressure induced by long-term GLP-1R blockade is associated with NHE3 stimulation and 
increased insulin circulating levels, they are still not sufficient to validate this hypothesis.  
Experimental and clinical evidence indicates that GLP-1R agonists, as well as DPP4 
inhibitors, confer therapeutic benefits in diabetic nephropathy beyond its anti-hyperglycemic 
effects27. These incretin-based agents confer renoprotection by reducing proteinuria, increasing 
GFR, and improving renal damage. The mechanisms underlying the renoprotective effects of 
GLP-1R agonists involve a reduction in oxidative stress, apoptosis signaling, inflammation, and 
protection from endothelial dysfunction. In line with the renoprotective actions of GLP-1R 
agonists, the present study reveals that long-term blockade of GLP-1R in SHR, a hypertensive 
model not associated with hyperglycemia, increases albuminuria, renal fibrosis, and 
inflammation.  An important caveat is that we cannot discern from our results whether GLP-1R 
blockade worsens renal damage because it increases blood pressure or if inhibition of renal GLP-
1R signaling per se may promote albuminuria, fibrosis, and inflammation. Interestingly, an in 
vitro study conducted in mesangial cells demonstrated that GLP-1 completely blocked the 
angiotensin II-induced generation of reactive oxygen species, NF-κB activation, up-regulation of 
mRNA levels of intercellular adhesion molecule-1 and plasminogen activator inhibitor-116. 
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These antioxidant and anti-inflammatory actions of GLP-1 were dependent on PKA activation16 
and suggest that GLP-1R signaling may indeed be directly responsible for the renoprotection.  
 
PERSPECTIVES 
 Evidence from clinical trials supports that GLP-1R agonists are able to reduce 
cardiovascular events and all-cause mortality as well as the progression of kidney disease in 
T2D. Apart from lowering glycemia, the cardioprotective benefits of the GLP-1R agonists may 
be attributable, at least in part, by their antihypertensive action. To the best of our knowledge, 
this is the first study to demonstrate that endogenous GLP-1R signaling exerts a physiologically 
relevant effect on blood pressure control. As such, GLP-1 may not only be a target for 
therapeutic intervention, but likely may contribute to the development and/or maintenance of 
hypertension. Further studies are warranted to elucidate the potential role of impaired renal GLP-
1R signaling in the pathogenesis of hypertension. 
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NOVELTY AND SIGNIFICANCE 
 
1) What Is New? 
§  Several studies have consistently reported the diuretic, natriuretic, and antihypertensive 
effects of pharmacological GLP-1R activation. However, whether signaling through 
GLP-1R influences blood pressure at baseline has never been investigated previously. 
§ This is the first study that tested the hypothesis that endogenous GLP-1R signaling 
contributes to blood pressure control and to shed light upon its underlying mechanisms.  
2) What Is Relevant? 
§ GLP-1R signaling at baseline contributes to blood pressure control and exerts tonic 
actions on proximal tubule NHE3-mediated sodium reabsorption, intrarenal RAS, and on 
insulin sensitivity.  
§ Impaired GLP-1R signaling may contribute to the pathogenesis of hypertension, among 
other cardiovascular, renal, and metabolic diseases.  
3) Summary 
 In this study, we administered the GLP-1R antagonist exendin-9 to both hypertensive and 
normotensive rats in an attempt to validate the hypothesis that endogenous GLP-1R signaling 
plays a role in blood pressure control. Our results provide novel evidence that endogenous GLP-
1R signaling regulates systolic blood pressure, which may be attributable, at least in part, to its 
tonic actions on the proximal tubule NHE3-mediated sodium reabsorption, intrarenal renin-






Figure 1 – Effects of long-term blockade and activation of GLP-1R on blood pressure of SHR 
and Wistar rats. (A-B) Tail-cuff blood pressure was measured before and weekly after drug 
treatment in (A) SHR (n = 18 rats/group) and (B) Wistar rats (n = 16 rats/group). (C-H) Before 
euthanasia, rats were submitted to cannulation of the carotid artery for direct measurement of (C-
D) SBP and (E-F) DBP of SHR and Wistar rats. The values represent individual measurements 
and the means ± SEM. *P<0.05 **P<0.01 ***P<0.001 vs. Ctrl and †††P<0.001 vs. Ex9. 
 
Figure 2 – Effects of long-term blockade and activation of GLP-1R on extracellular volume 
homeostasis and lithium clearance in SHR and Wistar rats. A-D: SHR and Wistar rats treated 
with saline (Ctrl), exendin-9 (Ex9) or exenatide (Ex4) were challenged with an intraperitoneal 
bolus of warmed saline equivalent of 10% of their body weight and placed into metabolic cages 
for 3-h urine collection. (A-B) The percentage of the fluid load that was excreted within 3 hours 
of the saline challenge in SHR (A) and Wistar rats (B). (C-D) The percentage of the sodium load 
that was excreted within 3 hours of the saline challenge in SHR and Wistar rats. (E-F) Lithium 
clearance of SHR and Wistar rats. The values represent individual measurements and the means ± 
SEM. *P<0.05 **P<0.01 vs. Ctrl and †††P<0.001 vs. Ex9. 
 
Figure 3 - Effects of long-term blockade and activation of GLP-1R on the phosphorylation 
levels of NHE3 in the renal cortex of SHR and Wistar rats. Levels of phosphorylated (PS552-
NHE3) and total NHE3 were determined by immunoblotting in the renal cortex of (A) SHR and 
(B) Wistar rats treated with saline (Ctrl), exendin-9 (Ex9) or exenatide (Ex4). Graphical 
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representation of the ratio of phosphorylated NHE3 to total NHE3. The values represent 
individual measurements and the means ± SEM. *P<0.05 **P<0.01 vs. Ctrl and †††P<0.001 vs. 
Ex9. 
 
Figure  4 – Effects of long-term blockade and activation of GLP-1R on components of the 
intrarenal RAS. (A-B) The urinary angiotensinogen to creatinine ratio in (A) SHR and (B) 
Wistar rats treated with vehicle (Ctrl), exendin-9 (Ex9) or exenatide (Ex4). (C-D) The renal 
cortical angiotensin II (Ang II) content in (C) SHR and (D) Wistar rats. The values represent 
individual measurements and the means ± SEM. *P<0.05 **P<0.01 ***P<0.001 vs. Ctrl and 
††P<0.01 †††P<0.001 vs. Ex9. 
 
Figure  5 – Effects of long-term blockade and activation of GLP-1R on glucose tolerance 
and insulin resistance in SHR and Wistar rats. (A-B) Oral glucose tolerance tests were 
performed following an 8-hour fast on (A) SHR and (B) Wistar rats treated with vehicle (Ctrl), 
exendin-9 (Ex9) or exenatide (Ex4) after an oral administration of glucose (2 g/kg of body 
weight). Glucose area under the curve (AUC) values were calculated.  (C-D) Fasting serum 
insulin concentration in drug or vehicle-treated (C) SHR and (D) Wistar rats. (E-F) HOMA-IR 
index was calculated from fasting serum glucose and fasting serum insulin in (E) SHR and (F) 
Wistar rats. The values represent individual measurements and the means ± SEM. *P<0.05 
**P<0.01 ***P<0.001 vs. Ctrl and †P<0.05 ††P<0.01 †††P<0.001 vs. Ex9. 
 
Figure 6 – Systemic treatment with the GLP-1R antagonist exendin-9 or the agonist 
exenatide affects renal cortical PKA activity. (A-B) Representative immunoblotting and 
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quantitation by densitometry of all phospho-PKA proteins in the renal cortex of (A) SHR and (B) 
Wistar rats treated with saline (Ctrl), exendin-9 (Ex9) or exenatide (Ex4). The values represent 
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